Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study of Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma With Homologous Recombination (HR) Mutation a Single-center Open-label Exploratory Clinical Trial

Next Previous
Search
Trial Profile

Phase Ib Study of Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma With Homologous Recombination (HR) Mutation a Single-center Open-label Exploratory Clinical Trial

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Fuzuloparib (Primary) ; Temozolomide (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Mar 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2027.
    • 05 Mar 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.
    • 05 Mar 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top